Onglyza saxagliptin regulatory update

FDA’s Endocrinologic and Metabolic Drugs Advisory Committee recommended that the agency add language about potential risks of heart failure to the labels of 2 dipeptidyl peptidase-4 ( DPP-4; CD26) inhibitors to treat diabetes -- Onglyza saxagliptin from AstraZeneca and Nesina alogliptin from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka,

Read the full 483 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE